CY1119805T1 - Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων - Google Patents

Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων

Info

Publication number
CY1119805T1
CY1119805T1 CY20171101264T CY171101264T CY1119805T1 CY 1119805 T1 CY1119805 T1 CY 1119805T1 CY 20171101264 T CY20171101264 T CY 20171101264T CY 171101264 T CY171101264 T CY 171101264T CY 1119805 T1 CY1119805 T1 CY 1119805T1
Authority
CY
Cyprus
Prior art keywords
administration
delivery system
drug delivery
aquatically
absolute
Prior art date
Application number
CY20171101264T
Other languages
English (en)
Inventor
Julian Aleksov
Igor Lokot
Original Assignee
Ardenia Investments Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40795732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119805(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardenia Investments Ltd. filed Critical Ardenia Investments Ltd.
Publication of CY1119805T1 publication Critical patent/CY1119805T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα σύστημα χορήγησης φαρμάκων για τη χορήγηση πτωχώς υδατοδιαλυτής φαρμακευτικώς ενεργής ουσίας, σε μια φαρμακευτική σύνθεση που περιλαμβάνει ένα τέτοιο σύστημα χορήγησης φαρμάκων, και σε μια μέθοδο για την παρασκευή ενός τέτοιου συστήματος χορήγησης φαρμάκων. Η εφεύρεση αναφέρεται επίσης σε μια μέθοδο για τον έλεγχο του μεγέθους σωματιδίων ή/και του σχήματος σωματιδίων ή/και της κατανομής μεγέθους σωματιδίων σε ένα τέτοιο σύστημα χορήγησης φαρμάκων, και σε μια μέθοδο για την αύξηση της ικανότητας φόρτωσης φαρμάκων των σωματιδίων. Περαιτέρω η εφεύρεση αναφέρεται επίσης στη χρησιμοποίηση ενός τέτοιου συστήματος χορήγησης φαρμάκων για την παρασκευή ενός φαρμάκου για τη θεραπευτική αγωγή καρκίνου.
CY20171101264T 2007-12-19 2017-12-04 Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων CY1119805T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2007/001127 WO2009078754A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of poorly water soluble pharmaceutically active substances
PCT/SE2008/051515 WO2009078802A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Publications (1)

Publication Number Publication Date
CY1119805T1 true CY1119805T1 (el) 2018-06-27

Family

ID=40795732

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101264T CY1119805T1 (el) 2007-12-19 2017-12-04 Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
CY2019021C CY2019021I1 (el) 2007-12-19 2019-04-24 Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2019021C CY2019021I1 (el) 2007-12-19 2019-04-24 Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων

Country Status (27)

Country Link
US (4) US8999382B2 (el)
EP (1) EP2231189B1 (el)
JP (1) JP5466172B2 (el)
KR (1) KR101572703B1 (el)
CN (1) CN101951956B (el)
AU (1) AU2008339099B2 (el)
BR (1) BRPI0821740B1 (el)
CA (1) CA2709266C (el)
CY (2) CY1119805T1 (el)
DK (1) DK2231189T3 (el)
EA (1) EA015247B1 (el)
ES (1) ES2650242T3 (el)
FR (1) FR19C1030I1 (el)
HR (1) HRP20171796T1 (el)
HU (1) HUE034684T2 (el)
LT (2) LT2231189T (el)
LU (1) LUC00117I2 (el)
MX (1) MX2010006914A (el)
MY (2) MY157187A (el)
NL (1) NL300987I9 (el)
NO (2) NO2231189T3 (el)
NZ (1) NZ586859A (el)
PL (1) PL2231189T3 (el)
PT (1) PT2231189T (el)
SI (1) SI2231189T1 (el)
WO (2) WO2009078754A1 (el)
ZA (1) ZA201004685B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
CA2759332A1 (en) * 2009-04-21 2010-10-28 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
DK2575876T3 (en) 2010-05-26 2018-03-12 Selecta Biosciences Inc MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) * 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
WO2021259472A1 (en) * 2020-06-24 2021-12-30 Oasmia Pharmaceutical Ab Micellar docetaxel for use in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
EP1534672B1 (en) * 2002-07-23 2013-05-01 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
US7259984B2 (en) * 2002-11-26 2007-08-21 Cornell Research Foundation, Inc. Multibit metal nanocrystal memories and fabrication
JP2006199590A (ja) 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
WO2005089106A2 (en) 2004-02-27 2005-09-29 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2007001356A2 (en) * 2004-09-10 2007-01-04 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078755A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Also Published As

Publication number Publication date
MY157186A (en) 2016-05-13
HRP20171796T1 (hr) 2018-01-26
EP2231189B1 (en) 2017-09-06
WO2009078802A1 (en) 2009-06-25
MY157187A (en) 2016-05-13
PT2231189T (pt) 2017-12-12
AU2008339099B2 (en) 2015-08-13
NO2231189T3 (el) 2018-02-03
US9993438B2 (en) 2018-06-12
EA015247B1 (ru) 2011-06-30
KR20100094575A (ko) 2010-08-26
CY2019021I2 (el) 2019-11-27
NL300987I9 (nl) 2019-05-16
MX2010006914A (es) 2010-11-10
FR19C1030I1 (fr) 2019-06-21
NO2019023I1 (no) 2019-05-08
SI2231189T1 (en) 2018-03-30
PL2231189T3 (pl) 2018-03-30
WO2009078754A1 (en) 2009-06-25
CA2709266C (en) 2017-09-26
ZA201004685B (en) 2011-03-30
DK2231189T3 (en) 2017-12-11
CN101951956B (zh) 2012-10-17
EP2231189A1 (en) 2010-09-29
LUC00117I2 (el) 2024-05-22
BRPI0821740A2 (pt) 2020-02-27
CY2019021I1 (el) 2019-11-27
EA200802350A3 (ru) 2009-10-30
EA200802350A2 (ru) 2009-06-30
US20150164819A1 (en) 2015-06-18
US8999382B2 (en) 2015-04-07
CN101951956A (zh) 2011-01-19
NZ586859A (en) 2012-06-29
AU2008339099A1 (en) 2009-06-25
JP2011507838A (ja) 2011-03-10
USRE49742E1 (en) 2023-12-05
US20110014281A1 (en) 2011-01-20
JP5466172B2 (ja) 2014-04-09
NL300987I2 (el) 2019-05-09
ES2650242T3 (es) 2018-01-17
LTPA2019508I1 (lt) 2019-05-10
USRE49741E1 (en) 2023-12-05
EP2231189A4 (en) 2013-10-09
BRPI0821740B1 (pt) 2021-05-18
KR101572703B1 (ko) 2015-11-27
CA2709266A1 (en) 2009-06-25
LT2231189T (lt) 2017-12-27
HUE034684T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CY1119805T1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
Giuliano et al. Drug-loaded biocompatible nanocarriers embedded in poloxamer 407 hydrogels as therapeutic formulations
Mehta et al. Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
Illum Nasal drug delivery—Recent developments and future prospects
Borges et al. Oral films: Current status and future perspectives II—Intellectual property, technologies and market needs
Wang et al. The bone, the joints and the Balm of Gilead
Fang et al. Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy
WO2008103409A3 (en) Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis
Cho et al. 3D printing of poloxamer 407 nanogel discs and their applications in adjuvant ovarian cancer therapy
MX2010002409A (es) Composiciones y metodos para la distribucion de farmacos escasamente solubles.
Sharma et al. Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
WO2019155416A3 (en) A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
ATE441402T1 (de) Verbessertes medizinprodukt
Bazeed et al. Pancreatic cancer: challenges and opportunities in locoregional therapies
WO2006060325A3 (en) Coated drug delivery formulations
CY1121145T1 (el) Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας
WO2014075203A1 (es) Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina
Smagina et al. Polymeric gel systems cytotoxicity and drug release as key features for their effective application in various fields of addressed pharmaceuticals delivery
Hariharan et al. Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas
Di Mascolo et al. μMESH-Enabled Sustained Delivery of Molecular and Nanoformulated Drugs for Glioblastoma Treatment
Lin et al. Advances in microneedle-based therapy for bone disorders
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
Caliceti et al. Advances in drug delivery and biomaterials: Facts and vision